CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have earned an average rating of “Moderate Buy” from the nineteen analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, ten have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $67.50.

Several research analysts have commented on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price target on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Friday, July 17th. Citigroup restated a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Monday, September 28th. UBS Group reissued a “buy” rating on shares of CRISPR Therapeutics in a report on Friday. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st.

CRISPR Therapeutics Stock Down 2.8%

Shares of CRSP opened at $50.10 on Friday. CRISPR Therapeutics has a 1 year low of $44.12 and a 1 year high of $75.06. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The stock’s fifty day moving average price is $55.12 and its two-hundred day moving average price is $53.18.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The business had revenue of $10.18 million for the quarter. As a group, equities research analysts anticipate that CRISPR Therapeutics will post -4.48 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Ali Behbahani sold 13,679 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the transaction, the director owned 16,637 shares of the company’s stock, valued at approximately $949,806.33. This represents a 45.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James Kasinger sold 10,400 shares of the stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $60.24, for a total transaction of $626,496.00. Following the completion of the transaction, the general counsel owned 94,784 shares of the company’s stock, valued at approximately $5,709,788.16. The trade was a 9.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 26,069 shares of company stock valued at $1,526,910 in the last ninety days. 5.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its holdings in shares of CRISPR Therapeutics by 92.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock worth $69,000 after purchasing an additional 597 shares in the last quarter. Green Alpha Advisors LLC boosted its holdings in CRISPR Therapeutics by 1.8% in the third quarter. Green Alpha Advisors LLC now owns 56,786 shares of the company’s stock worth $3,141,000 after purchasing an additional 982 shares during the last quarter. Farther Finance Advisors LLC raised its stake in CRISPR Therapeutics by 43.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 11,426 shares of the company’s stock valued at $632,000 after buying an additional 3,470 shares during the last quarter. Congress Asset Management Co. grew its holdings in shares of CRISPR Therapeutics by 1.6% in the third quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock worth $6,153,000 after acquiring an additional 1,777 shares during the period. Finally, Versant Capital Management Inc lifted its holdings in CRISPR Therapeutics by 131.8% in the third quarter. Versant Capital Management Inc now owns 1,078 shares of the company’s stock valued at $60,000 after acquiring an additional 613 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.